Reverse Stock Split

RNS Number:0027M
Amarin Corporation Plc
17 January 2008







          AMARIN ANNOUNCES SHAREHOLDER APPROVAL OF REVERSE STOCK SPLIT



LONDON, United Kingdom, January 17, 2008 - Amarin Corporation plc ("Amarin" or
the "Company") announces that, at a General Meeting today, its shareholders
approved a 1 for 10 reverse split of each of its Ordinary Shares.



The reverse split, comprising the consolidation of every 10 existing Ordinary
Shares of £0.05 each into one Ordinary Share of £0.50 each, will take place at
5.00pm GMT today, January 17, 2008.  The consolidated Ordinary Shares of £0.50
each will be admitted to trading on AIM and IEX at 8.00am GMT, January 18, 2008,
under the new ISIN GB00B29VL935.  Following the reverse split, there will be
14,003,237 Ordinary Shares of £0.50 each in issue.



Each American Depositary Share ("ADS") will continue to represent one Ordinary
Share following the reverse split.  Accordingly, the proposed 1 for 10 reverse
split of Ordinary Shares will have a corresponding effect on all outstanding
ADSs and the corresponding effective date for ADSs will be January 18, 2008.



Under customary Nasdaq practice, with effect from January 18, 2008, and for a
period of 20 trading days thereafter, a "D" will be appended to Amarin's Nasdaq
ticker symbol and during that period Amarin's Nasdaq ticker symbol will appear
as "AMRND".



About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.



Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis clinical program and preclinical programs in neuromuscular, neuronal
degenerative and inflammatory diseases; Miraxion for Huntington's disease; two
programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is
initiating a series of cardiovascular preclinical and clinical programs to
capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin also has two proprietary technology platforms, a
lipid-based technology platform for the targeted transport of molecules through
the liver and/or to the brain, and a unique mRNA technology based on cholinergic
neuromodulation.



Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.  With effect from January 18, 2008, and for a
period of 20 trading days thereafter, a "D" will be appended to Amarin's Nasdaq
ticker symbol and during that period Amarin's Nasdaq ticker symbol will appear
as "AMRND".





Contacts:

Amarin [phone]

Thomas Lynch Chief Executive Officer

Alan Cooke President and Chief Operating Officer

[e-mail]



Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields [phone]

Bruce Voss [phone]



Media:

Powerscourt [phone]

Rory Godson

Sarah Daly



Davy: [phone]

Ivan Murphy

Fergal Meegan



Ends.

This announcement has been issued through the Companies Announcement Service of

                           the Irish Stock Exchange.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ISEDGGMMZNDGRZM